Clinical Oncology
Volume 22, Issue 3 , Pages 173-178, April 2010

The Application of Positron Emission Tomography/Computed Tomography in Radiation Treatment Planning: Effect on Gross Target Volume Definition and Treatment Management

  • Ş. İğdem

      Affiliations

    • Department of Radiation Oncology, İstanbul Bilim University, School of Medicine, Cemil Aslan Güder sok 8 Gayrettepe, 34340 İstanbul, Turkey
    • Corresponding Author InformationAuthor for correspondence: Ş. İğdem, Department of Radiation Oncology, İstanbul Bilim University, School of Medicine, Cemil Aslan Güder sok 8 Gayrettepe, 34340 Istanbul, Turkey. Tel: +90-212-3365570; Fax: +90-212-2882969.
  • ,
  • G. Alço

      Affiliations

    • Department of Radiation Oncology, Florence Nightingale Gayrettepe Hospital, İstanbul, Turkey
  • ,
  • T. Ercan

      Affiliations

    • Department of Radiation Oncology, Florence Nightingale Gayrettepe Hospital, İstanbul, Turkey
  • ,
  • B. Ünalan

      Affiliations

    • Department of Nuclear Medicine, Florence Nightingale Gayrettepe Hospital, İstanbul, Turkey
  • ,
  • B. Kara

      Affiliations

    • Department of Radiology, Florence Nightingale Şişli Hospital, İstanbul, Turkey
  • ,
  • G. Geceer

      Affiliations

    • Department of Radiology, Florence Nightingale Şişli Hospital, İstanbul, Turkey
  • ,
  • C. Akman

      Affiliations

    • Department of Radiology, Florence Nightingale Şişli Hospital, İstanbul, Turkey
  • ,
  • F.O. Zengin

      Affiliations

    • Department of Radiation Oncology, Florence Nightingale Gayrettepe Hospital, İstanbul, Turkey
  • ,
  • S. Atilla

      Affiliations

    • Department of Radiation Oncology, Florence Nightingale Gayrettepe Hospital, İstanbul, Turkey
  • ,
  • S. Okkan

      Affiliations

    • Department of Radiation Oncology, İstanbul Bilim University, School of Medicine, Cemil Aslan Güder sok 8 Gayrettepe, 34340 İstanbul, Turkey

Received 25 November 2009; received in revised form 21 December 2009; accepted 23 December 2009.

Abstract 

Aims

To analyse the effect of the use of molecular imaging on gross target volume (GTV) definition and treatment management.

Materials and methods

Fifty patients with various solid tumours who underwent positron emission tomography (PET)/computed tomography (CT) simulation for radiotherapy planning from 2006 to 2008 were enrolled in this study. First, F-18 fluorodeoxyglucose (FDG)-PET and CT scans of the treatment site in the treatment position and then a whole body scan were carried out with a dedicated PET/CT scanner and fused thereafter. FDG-avid primary tumour and lymph nodes were included into the GTV. A multidisciplinary team defined the target volume, and contouring was carried out by a radiation oncologist using visual methods. To compare the PET/CT-based volumes with CT-based volumes, contours were drawn on CT-only data with the help of site-specific radiologists who were blind to the PET/CT results after a median time of 7 months.

Results

In general, our PET/CT volumes were larger than our CT-based volumes. This difference was significant in patients with head and neck cancers. Major changes (≥25%) in GTV delineation were observed in 44% of patients. In 16% of cases, PET/CT detected incidental second primaries and metastatic disease, changing the treatment strategy from curative to palliative.

Conclusions

Integrating functional imaging with FDG-PET/CT into the radiotherapy planning process resulted in major changes in a significant proportion of our patients. An interdisciplinary approach between imaging and radiation oncology departments is essential in defining the target volumes.

Key words: Image fusion, PET/CT, radiotherapy planning, volume definition

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0936-6555(10)00006-3

doi:10.1016/j.clon.2010.01.003

Clinical Oncology
Volume 22, Issue 3 , Pages 173-178, April 2010